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Purpose: To investigate the anti-diabetic, hepatoprotective and lipid homeostatic activity of 
Cinnamomum zeylanicum aqueous bark extract on streptozotocin (STZ)-induced type-I diabetic rats.  
Methods: The animals were divided into three groups (n = 6). of normal rats; streptozotocin-induced 
diabetic rats; and diabetic rats treated with 200 mg/kg of the aqueous bark extract, respectively. 
Treatment was via the oral route for 15 days. Various biochemical parameters, including lipid profile and 
glycogen biosynthesis were analysed. Similarly, differential regulation and expression of glucose 
homeostatic enzymes were evaluated in order to validate the anti-diabetic activity of the extract. 
Results: Total cholesterol (TC), triglyceride (TG), LDL-cholesterol (LDL) and VLDL-cholesterol (VLDL) 
levels decreased significantly (p < 0.05) in the diabetic animals by 12.5, 23.86, 14.96 and 20 %, 
respectively, compared to their initial values. The extract increased HDL-cholesterol (HDL) and tissue 
glycogen levels by 25.0 and 172.3 %, respectively, in diabetic rats. Similarly, differential regulation and 
expression of glucose homeostatic enzymes, namely, glucokinase (GK), glucose-6-phosphatase 
(G6Pase), phosphoenol pyruvate carboxykinase (PEPCK), glucose-6-phosphate dehydrogenase (G-6-
PDH) and Insulin II (Ins II), showed significant improvement upon extract treatment in STZ-induced 
diabetic rats.  
Conclusion: These results demonstrate the anti-diabetic, and hypolipidemic activities of Cinnamomum 
zeylanicum aqueous bark extract in diabetic rats. 
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During the last decades of the 20th century, 
there was an increase in the incidence of 
Type 1 diabetes mellitus (T1DM) with several 
million people already affected around the 
globe. A variety of factors, ranging from 
immune dysregulation to environmental 
triggers have been suggested as contributing 
to this increasing trend [1,2]. In spite of the 
introduction of new potential treatments, 
diabetes and related complications continue 
to be a major medical problem. The 
possibility of strong side effects associated 
with the current pre-clinical protocols 
developed in rodents is a major concern and 
unacceptable in humans [3].  
 
Recently, the role of herbal remedies has 
come into focus due to the side effects 
associated with current protocols in the 
treatment and containment of diabetes and 
its associated complications. More than 400 
plants with glucose-lowering effects are 
known in India [4], some of which have been 
tested and their active components are being 
isolated. Thus, there is continuing search for 
new anti-diabetic drugs.  
 
Cinnamon is one of the traditional herbs used 
as a remedy for diabetes. Cinnamon tree 
(Cinnamomum zeylanicum B. Lauraceae) is a 
native of South-west Asia, including Sri 
Lanka, and the bark is sold in powder, 
scrapings and branches. Cinnamon extract 
has also been shown to enhance glucose 
utilization in vivo in a dose-dependent 
manner, as well as potentiates insulin-
stimulated tyrosine phosphorylation of IR-β, 
insulin receptor-1 (IRS-1) and Insulin receptor 
substrate-1 (IRS-1) association with 
phosphotidyl inositol-3 kinase (PI 3-kinase), 
without affecting their protein content in 
skeletal muscle [5].  
Cinnamon extract has a regulatory role in a 
type-2 diabetic animal model (C57BIKsj 
db/db). It was found to reduce blood glucose 
in a dose-dependent manner, as well as 
triglyceride, total cholesterol and intestinal α-
glycosidase activity, but enhances serum 
insulin and HDL-cholesterol levels. It also 
shows blood glucose-suppressing effect by 
improving insulin sensitivity or slowing 
absorption of carbohydrates in the small 
intestine [6].  
 
Widespread achievement of therapeutic 
glycemic targets remains an elusive goal for 
type-1 diabetic subjects. To date, only one 
study of the role of cinnamon in glycemic 
control among adolescents with type-1 
diabetes has been reported [7]. In this 
context, the aim of the present study was to 
investigate new and strong evidence of the 
hypolipidemic and anti-diabetic activity of 
Cinnamomum zeylanicum aqueous bark 






Cinnamon bark was purchased from an 
ayurvedic store in Kannur, Kerala, India in 
December 2008. The plant material was 
identified as per Auyervada literature, by a 
local expert in herbal gardens, and confirmed 
by Dr. H.S. Dhaliwal, Professor of Plant 
Biotechnology, Department of Biotechnology, 
Indian Institute of Technology, Roorkee, 
India. 
 
Preparation of the bark extract  
 
Cinnamon bark (~500 g) was thoroughly 
powdered and kept airtight in cool, dry and 
dark conditions. Approximately 50 g was 
placed in a soxhlet apparatus and extracted 
in aqueous medium for 60 h. The extract was 
concentrated in a rotary evaporator at 
reduced pressure to give a yield of 10 % 
which was then lyophilized (ScanVac 





The study was conducted on 26 male Wistar 
rats, 8 - 10 weeks old, weighing 160 - 180 g, 
and purchased from the animal facility centre 
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at NIPER, Chandigarh, India. They were 
housed in colony cages (maximum 5 
rats/cage) at an ambient temperature of 25 ± 
2 °C with 12 h/12 h light/dark cycle. The rats 
were fed normal diet purchased from 
commercial vendors and were randomly 
divided into three groups (n = 6): Group 1 
(untreated, control); Group 2 (streptozotocin-
induced diabetic); and Group 3 –
streptozotocin-induced diabetic rats treated 
with the extract. The rats were acclimatized 
for a period of a further 2-3 weeks in the new 
environment prior to initiation of the 
experiment. The animals were deprived of 
food at least 16 h but were allowed free 
access to drinking water. All the experiments 
were performed as per the guidelines of the 
Institutional Animal Ethics Committee which 
also gave approval for the tests (registration 
number: 563/02/a/CPCSEA), and the national 
guidelines of Committee for the Purpose of 
Control and Supervision of Experiments on 
Animals, as applicable. The animals were 
handled according to the standard protocols 
for the use of laboratory animals [8]. 
 
Induction of diabetes mellitus 
 
A freshly prepared solution of streptozotocin 
(65 mg/kg body weight) in 0.1M citrate buffer 
(pH 4.5) was injected intraperitoneally to the 
overnight fasted rats. The rats in the control 
group were injected with sodium citrate buffer 
(vehicle). Fasting blood glucose (FBG) was 
evaluated at the time of induction of diabetes 
while postprandial glucose (PPG) was 
checked regularly until stable hyperglycemia 
was achieved. The rats having marked 
hyperglycemia (FBG > 250 mg/dl) were 
selected for the study as stable 
hyperglycemic animals [9].  
 
Serum preparation   
 
Serum was prepared following routine 
procedure. Briefly, blood samples were 
withdrawn from retro orbital sinus using non-
heparinised capillary tubes, collected in dried 
centrifuge tubes and allowed to clot. Serum 
was separated from the clot by centrifugation 
for five min at 800 x g in a fixed rotor 
centrifuge at room temperature. The serum 
was collected carefully using a Pasteur 
pipette and kept at -20 °C until enzyme 
analysis.  
 
Determination of lipid profile and tissue 
glycogen  
 
Total cholesterol, high density lipoprotein 
(HDL) cholesterol and triglyceride (TG) levels 
in serum were determined according to the 
instructions of the manufacturer (Transasia 
Bio Medical Limited, Himachal Pradesh, 
India). For the determination of very low 
density lipoprotein (VLDL) and low density 
lipoprotein (LDL) cholesterol, Friedwald’s 
formulae was used which gives: VLDL 
cholesterol as triglyceride/5, and LDL 
cholesterol as total cholesterol – (VLDL + 
HDL cholesterol). The assessment of tissue 
glycogen from liver was carried out by the 
method of Sadasivam [10]. The liver was 
homogenized in hot 80 % ethanol to a tissue 
concentration of 100 mg/ml and then 
centrifuged at 8000 x g for 20 min. The 
residue was collected and allowed to dry over 
a hot water bath. To the residue, 5 ml of 
distilled water and 6 ml of 52 % perchloric 
acid was added, and the mixture subjected to 
extraction at 0 oC for 20 min. The mixture was 
centrifuged at 8000 x g for 15 min. The 
supernatant (0.2 ml) was transferred to a 
graduated test tube and the volume made up 
to 1ml with distilled water. Graded standards 
were prepared using 0.1, 0.2, 0.4, 0.6, 0.8 
and 1.0 ml of the working standard and the 
volume of each of these made up to 1ml with 
distilled water. To each of the test tubes, 4 ml 
of anthrone reagent was added. The tubes 
were heated in a boiling water bath and then 
allowed to cool to room temperature. The 
intensity of the green to dark green colour of 
the solution generated was recorded 
spectrophotometrically at 630 nm. The 
amount of glycogen was computed from 
calibration (standard) curve derived from 
standard glucose solution. The amount of 
glycogen in the tissue sample was expressed 
in µg/mg tissue. 
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Semi-quantitative reverse transcriptase-
polymerase chain reaction RT–PCR 
 
Total RNA were extracted from treated and 
diabetic rat liver and pancreas, respectively 
using GenEluteTM Mammalian Total RNA 
Miniprep Kit (Sigma-Aldrich, U.S.A). The 
isolated RNA samples were quantified, equal 
amounts of which were reverse transcribed 
with the aid of the RT–PCR kit (Bangalore 
Genei, Bangalore, India) according to 
manufacturer’s instructions. PCR was 
performed by denaturing at 94 °C for 60 s, 
annealing at various temperatures 
(depending on primer pairs) and by extension 
at 72 °C for 60 s; 35 additional cycles were 
used for amplification. The primer pairs used 











product of β-Actin gene, using β-Actin-F5’-
CAGCGGAACCGCTCATTGCCAATGG-3’, β-
Actin-R5’-TCACCCACACTGTGCCCCATCT-
ACGA-3’ primers, was used as internal 
standard. The PCR products were then 
separated on 2 % agarose gel and visualized 
in a gel documentation system (Bio Rad, 
USA). The intensity of the bands on gels was 





All values are presented as mean ± SEM 
(standard error of mean). Statistical 
significance was evaluated by independent 
two-population t-test using Origin software 
(Origin Lab Corporation, USA), version 6.1. P 







There was a significant reduction (p <0.05) of 
12.5, 23.86, 14.96 and 20 % in TC, TG, LDL-
cholesterol and VDL-cholesterol levels, 
respectively, whereas a significant (p <0.05) 
increase of HLD-cholesterol in diabetic rats 
by 25 %, as compared to their initial values 
(Table 1).  
 
Glycogen level in liver  
 
Tissue glycogen content showed a significant 
increase (p < 0.05) of 172.3 %, after oral 
administration of the extract in STZ-induced 
diabetic rats (Table 1). 
 
Gene expression profile 
 
As   shown   in   Fig. 1,  a marked  change in  
 
Table 1: Serum lipid levels and tissue glycogen content following administration of C. zeylanicum aqueous 
bark extract to streptozotocin-induced diabetic rats. 
 
Each value is mean  S.E.M., n = 6; * statistically significant different compared to diabetic group (p < 
0.05).   












Tissue glycogen   
content (µg/g) 
Normal 141±3.8   
40.0±2.1    
78±3.1  113±3.7  23±1.9  49.5±3.4 
Diabetic 208±8.2   
25.6±1.5 
147±7.4  176±7.2   35±1.4  16.3±2.3 
Treated 182±4.7*   
32.0±2.8* 
25±3.8* 134±6.6*    28±0.6* 44.3±3.4* 
Hassan et al 
Trop J Pharm Res, June 2012;11 (3): 433 
expression profile of mRNA for all the 
glucose hepatic regulatory enzymes was 
observed in diabetic treated groups (Group 
3). The hepatic level of glucokinase and 
glucose-6 phosphate dehydrogenase 
increased 2-fold in treated diabetic rats while 
pancreatic insulin II expression increased 
several-fold, compared to untreated diabetic 
rats. Furthermore, there was a clear 
reduction in the expression patterns of 
gluconeogenic enzymes, G6Pase and 
PEPCK, by almost 2-fold, compared to 
diabetic rats (Group 2). In contrast, hepatic β-
Actin showed uniform expression in all the 





Fig 1: RT-PCR analysis of (A) liver mRNA 
expression of alpha actin, (B) liver mRNA 
expression of glucokinase, (C) liver mRNA 
expression of glucose-6-phosphate 
dehydrogenase, (D) liver mRNA expression of 
glucose-6-phosphatase, (E) liver mRNA 
expression of phosphoenol pyruvate 
carboxykinase, and (F) pancreas mRNA 
expression of Insulin II, before and after treatment 
of extract in diabetic rats. Note: M, N, D and T 
denote DNA ladder, normal, diabetic and treated 





Streptozotocin has been shown to induce 
free radical production and cause tissue 
injury. The pancreas is especially susceptible 
to the action of streptozotocin-induced free 
radical damage. It was reported earlier that 
cinnamon extract is capable of acting as a 
free radical scavenger in vitro [11]. A single 
intraperitoneal injection of streptozotocin (65 
mg/kg) induced damage that mimicked 
insulin-dependent diabetic (T1DM) conditions 
to a great extent. The present study was 
designed to determine the lipid profile, tissue 
glycogen content and glycolytic, gluco-
neogenic gene expression profile in both 
diabetic (control) and treated rats. 
 
In order to understand the molecular 
mechanism of action of Cinnamomum 
zeylanicum aqueous extract as anti-
diabetogenic agent, the expression level of 
glucokinase, glucose-6-phosphatase, glucose 
-6-phosphate dehydrogenase, Insulin II and 
phosphoenol pyruvate carboxykinase was 
analyzed. These enzymes are directly linked 
to glucose homeostasis and production of 
glycogen. Glucokinase is involved in the 
phosphorylation step of glucose during 
glycolysis. This enzyme was significantly 
reduced in the liver of diabetic rats and this 
may be the reason for the decrease in the 
utilization of glucose and increased blood 
glucose level [12]. The extract-treated 
diabetic rats showed increased activity of 
glucokinase that may lead to activation of 
glycolysis and increased utilization of glucose 
for energy production. Glucokinase that that 
leads to a reduction in the expression of 
G6Pase and PEPCK in response to extract 
treatment provides an additional clue to its 
role in carbohydrate metabolism [13]. The 
extract-treated diabetic rats showed 
increased expression of insulin II, compared 
to diabetic control. This is another possible 
reason for the normal blood glucose levels in 
extract-treated diabetic group.  
 
Glucose-6-phosphate dehydrogenase (G-6-
PDH) is the key enzyme for maintaining 
normal blood sugar level. Streptozotocin-
induced type-1 diabetes also develops due to 
reduction of G-6-PDH activity in the liver 
which obstructs glucose utilization via 
pentose phosphate pathway as this enzyme 
activity is under insulin stimulation [14]. The 
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expression of G-6-PDH increased after oral 
administration of the extract. These results 
clearly show the vibrant role of the extract in 
restoring the glucose homeostasis in STZ-
induced diabetic rats. 
 
Cardiovascular diseases are listed as the 
cause of death in 65 % of people suffering 
from diabetes [15]. Since lipid abnormalities 
accompanied with premature atherosclerosis 
are the major cause of cardiovascular 
diseases in diabetic patients, an ideal 
treatment for diabetes, in addition to glycemic 
control, should seek to achueve a favorable 
lipid profile. There was a significant decrease 
in TC, LDL, VLDL and TG levels as well as 
enhancement of the cardioprotective lipid, 
HDL, by 25 % in diabetic rats following 
extract treatment (Table 1). Increase in HDL-
cholesterol is associated with a decrease in 
coronary risk and most of the drugs that 
decrease total cholesterol also decrease 
HDL-cholesterol [16]. In the present study, 
the extract not only decreased total 
cholesterol but also enhanced HDL-
cholesterol significantly. 
 
High levels of TC and, more importantly, LDL 
cholesterol are major coronary risk factors 
[17]. Administration of the extract to diabetic 
rats lowered TC and LDL cholesterol by 12.5 
and 15 %, respectively. This is remarkable as 
diabetes is associated with coronary 
complications which constitute the major 
cause of morbidity and deaths in diabetic 
subjects. Biochemical studies suggest that 
TG itself is independently related to coronary 
heart disease [18] and most of the anti-
hypercholesterolemic drugs do not decrease 
TG levels but the extract lowered it by 23.9 % 
after treatment. The level of glycemic control 
is the major determinant of very low density 
lipoprotein and triglyceride concentrations 
[19]; improved glycemic control following 
extract treatment also resulted in decreased 
levels of serum VLDL and total triglyceride. 
This progressive change in lipid profile of the 
treated diabetic rats sheds some light on the 
mode of action of the extract as a positive 
stimulator of lipid homeostasis in 
streptozotocin-induced type-I diabetic rats.  
 
Glycogen is the primary intracellular storable 
form of glucose and its levels in liver is a 
direct reflection of insulin activity. Since 
streptozotocin causes selective destruction of 
β-cells of islets of Langerhans, resulting in 
marked decrease in insulin levels, it could be 
predicted that glycogen levels in liver 
decrease as the influx of glucose in the liver 
is inhibited in the absence of insulin [20]. Our 
study showed that the extract significantly 
improved hepatic glycogen levels in treated 
diabetic rats. This suggest thats one of the 
possible ways the extract exerts its effect is 





The aqueous bark extract of C. zeylanicum 
exhibits strong hypolipidemic activity in 
addition to its role in glucose homeostasis in 
diabetic animals. We believe that our findings 
brings forth new and strong evidence that the 
bark extract, if used as a glucose 
homeostatic agent, may also reverse 
dyslipidemia associated with type-1 diabetes 
and prevent cardiovascular complications 
which are prevalent in diabetic patients. 
Thus, there is need for further investigation of 
this extract with a view to the development of 
potent phytomedicine for type-1 diabetes 
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